Accessibility Menu
Amarantus BioScience logo

Amarantus BioScience(OTC) AMBS

Market Cap$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Amarantus BioScience last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-03
Amarantus BioScience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-27
1 month+0%USD 0.002026-07-02
3 month+0%USD 0.002026-04-30
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-07-11
3 year-99.87%USD 0.002023-08-04
5 year-99.99%USD 0.012021-08-04
Since inception-100%USD 11.702011-06-13

Amarantus BioScience Financials at a Glance

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$96.61K

Net Income (TTM)

-$1.75M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

45.58 (High)

Price

$0.00

Volume

10,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.25

Estimated Earnings Date

Nov 25, 2024

AMBS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Amarantus BioScience

Amarantus BioScience Holdings, Inc. is a biopharmaceutical firm focused on developing innovative diagnostic tools and therapeutic solutions. The company specializes in neurological disorders, psychiatric conditions, ophthalmology, and regenerative medicine.

Products and Services
  • LymPro test for Alzheimer's disease detection
  • MSPrecise DNA sequencing assay for multiple sclerosis
  • Eltoprazine for Parkinson's dyskinesia and ADHD treatment
Growth Outlook
  • Recent collaborations with U.S. Army Institute and Rutgers University enhance research capabilities
  • Expansion of diagnostic platforms targeting neurodegenerative diseases and oncology
  • Development of Engineered Skin Substitute for severe burn treatment
Financial Highlights
  • Q1 2023 revenue of 1,275, a decrease from Q4 2022
  • Net income for Q1 2023 was -52,026, reflecting ongoing operational challenges
  • Trailing twelve months (TTM) net profit margin stands at -49.95%
Amarantus BioScience Holdings, Inc. operates in a highly specialized sector, focusing on critical health issues that affect millions globally. The company's innovative diagnostic and therapeutic products aim to address significant unmet medical needs. Despite recent financial challenges, including a decrease in revenue and net income, the ongoing development of its product pipeline and strategic partnerships may position the company for future growth. The focus on neurological and psychiatric disorders, along with advancements in regenerative medicine, highlights the potential for impactful contributions to healthcare. Investors may find interest in the company's unique offerings and its commitment to addressing complex medical conditions.
AI Generated • Jul 11, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Gerald E. Commissiong

Website

www.amarantus.com

Headquarters

New York City, NY 10005, US

AMBS Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-281.13%

Net Income Margin

-4995.23%

Return on Equity

21.36%

Return on Capital

N/A

Return on Assets

-46.65%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

630.41M

Volume

10.00K

Avg. Volume

39.43K

Financials (TTM)

Gross Profit

$96.61K

Operating Income

-$271.10K

EBITDA

-$1.59M

Operating Cash Flow

-$1.49M

Capital Expenditure

$0.00

Free Cash Flow

-$1.49M

Cash & ST Invst.

$0.00

Total Debt

$19.12M

Amarantus BioScience Performance Analysis

Amarantus BioScience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 95,331N/A
Amarantus BioScience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-30N/A
Q32022-09-30449.7%
Q42022-12-31-61.8%
Q12023-03-31-94.5%
Amarantus BioScience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.02N/A
20222022-12-31USD -0.01-62.6%
Amarantus BioScience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-3083.3%
Q32022-09-30154.5%
Q42022-12-31-500.0%
Q12023-03-3195.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2023YOY CHG

Revenue

$1.28K

N/A

Gross Profit

$1.28K

N/A

Gross Margin

100.00%

N/A

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$50.00

N/A

Employees

12

N/A

Net Income

-$52.03K

+98.3%

EBITDA

-$60.00K

+98.0%

Quarterly Fundamentals

Name
Q1 2023YOY CHG

Total Cash

$0.00

-100.0%

Total Debt

$19.12M

-0.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$19.12M

-0.4%

Return on Assets

-46.65%

N/A

Return on Invested Capital

1.09%

N/A

Free Cash Flow

$7.97K

+100.3%

Operating Cash Flow

$7.97K

+100.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IBXGiBX Group, Inc.
$0.00+0.00%
PRMDPrimeMD Inc
$0.00+0.00%
ITMCItoco Inc.
$0.00+0.00%
ENDVEndonovo Therapeutics, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About AMBS

What is the current price of Amarantus BioScience?

Amarantus BioScience is trading at $0.00 per share.

What is the 52-week range for Amarantus BioScience?

Over the past 52 weeks, Amarantus BioScience has traded between $0.00 and $0.25.

How much debt does Amarantus BioScience have?

As of the most recent reporting period, Amarantus BioScience reported total debt of $19.14M.

How much cash does Amarantus BioScience have on hand?

Amarantus BioScience reported $0.00 in cash and cash equivalents in its most recent financial results.

What is Amarantus BioScience’s dividend yield?

Amarantus BioScience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services